Michael Makris/LinkedIn
Feb 28, 2026, 16:16
Michael Makris: Lower Doses of Hemlibra May Still Be Effective
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn about his recent commentary, adding:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Authors: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 15, 2026, 14:27Factor XIII and the Future of Anticoagulation in VTE
-
Jul 15, 2026, 14:26Matthew D. Neal: From Platelet Biology to Patient Impact at ISTH 2026
-
Jul 15, 2026, 14:15Sarah Richardson: Today, I Ask You to Stand with the Bleeding Disorders Community
-
Jul 15, 2026, 14:03Anna Randi: Imperial College London’s Vascular Haemostasis and Thrombosis Team Shines at ISTH 2026
-
Jul 15, 2026, 13:53Akhil Antony Konkoth: Galectin-9 Emerges as a Key Mediator of Venous Thromboinflammation
-
Jul 15, 2026, 13:48Sabine Eichinger: New Insights into Recurrence Risk After Provoked VTE at ISTH 2026
-
Jul 15, 2026, 13:44Shirley D’Sa: Vitamin B6 Offers a New Clue in the POEMS Syndrome Puzzle
-
Jul 15, 2026, 13:43Katarina Miljević: New Insights into Recombinant tPA and FXI Inhibition at ISTH 2026
-
Jul 15, 2026, 13:31Sandrine Meunier: ISTH 2026 Highlights Consensus on Pediatric Hemostatic Assessment